Listing 1 - 6 of 6 |
Sort by
|
Choose an application
Autoimmune Diseases --- Myasthenia Gravis --- Myasthenia gravis --- Myasthenic Syndromes, Congenital --- Myoneural junction --- Neuromuscular Junction --- Neuromuscular diseases --- Receptors, Cholinergic --- Thymoma --- immunology --- Pathophysiology --- physiopathology
Choose an application
In the era of precision medicine, the use of molecularly targeted therapies in selected patients has led to a paradigm change in cancer treatment. Multiple studies have demonstrated the benefits of therapies that are chosen based on the molecular profile of the tumor and also from the liquid biopsy. With genomics' increasing ability, a routine transcriptomics analysis of advanced/metastatic cancers is now feasible in most cancer hospitals, including community cancer centers. This is an unprecedented shift in the management of cancers irrespective of their organ types, which not only improved the outcome but also opened several new avenues in research and practice, such as immune-check-point inhibitors, tumor-TME co-evolution in the development of resistance, longitudinal liquid biopsies, biomarkers screening and the management of electronic medical records.This book brings together these crucial areas of investigation. The research presented here attempts to address the current issues to provoke thoughts for the future. The future of precision medicine will have to embrace a shift from in vitro, in vivo/PDX models for the mechanistic study to a more functional test based on the scientific interrogation of genomic data, in the form of functional precision medicine. We will also have to combat the element of noise in the multitudes of data and impart the regulatory structure to make judicious use of the data. The expectations for functional precision medicine are high. We aspire to witness a tremendous improvement in patient outcomes, from better to best, down the road that will match the clinical guidelines.
Medicine --- Oncology --- pediatric tumors --- tumor mutational burden --- TMB --- whole-exome sequencing --- gene panel sequencing --- immune checkpoint inhibitors --- glioblastoma prognosis --- overall survival --- extent of resection --- random forest --- Decision tree --- personalized precision oncology --- circulating free DNA --- liquid biopsy --- epidermal growth factor receptor --- tyrosine kinase inhibitor --- osimertinib --- comprehensive genomic profiling --- molecular genotyping --- intratumor heterogeneity --- multiple biopsies --- tumor evolution --- clonality classification --- strategic therapeutic intervention --- thymoma --- driver mutation --- sequencing --- molecular barcoding --- EGFR mutation --- EGFR-TKI --- cfDNA --- NGS --- digital enrichment --- next-generation sequencing --- solid cancer --- universal health-care system --- precision medicine --- presumed germline findings --- clinical guideline --- non-small cell lung cancer --- outcome --- adjuvant chemotherapy --- anaplastic lymphoma receptor tyrosine kinase --- HNSCC --- ctDNA --- tDNA --- DDR genes --- PARP inhibitors --- new drug development --- next-generation sequencing (NGS) --- open data --- regulatory reform --- tumor profiling test --- triple-negative breast cancer (TNBC) --- breast cancer --- targeted therapy --- TNBC subtypes --- immunotherapy --- cancer --- screening --- smoking --- electronic records --- PD-L1 --- cancer-associated fibroblasts --- resistance --- chemotherapy --- CTC --- immunocytochemistry --- parallel double-detection --- laboratory-friendly --- n/a
Choose an application
In the era of precision medicine, the use of molecularly targeted therapies in selected patients has led to a paradigm change in cancer treatment. Multiple studies have demonstrated the benefits of therapies that are chosen based on the molecular profile of the tumor and also from the liquid biopsy. With genomics' increasing ability, a routine transcriptomics analysis of advanced/metastatic cancers is now feasible in most cancer hospitals, including community cancer centers. This is an unprecedented shift in the management of cancers irrespective of their organ types, which not only improved the outcome but also opened several new avenues in research and practice, such as immune-check-point inhibitors, tumor-TME co-evolution in the development of resistance, longitudinal liquid biopsies, biomarkers screening and the management of electronic medical records.This book brings together these crucial areas of investigation. The research presented here attempts to address the current issues to provoke thoughts for the future. The future of precision medicine will have to embrace a shift from in vitro, in vivo/PDX models for the mechanistic study to a more functional test based on the scientific interrogation of genomic data, in the form of functional precision medicine. We will also have to combat the element of noise in the multitudes of data and impart the regulatory structure to make judicious use of the data. The expectations for functional precision medicine are high. We aspire to witness a tremendous improvement in patient outcomes, from better to best, down the road that will match the clinical guidelines.
pediatric tumors --- tumor mutational burden --- TMB --- whole-exome sequencing --- gene panel sequencing --- immune checkpoint inhibitors --- glioblastoma prognosis --- overall survival --- extent of resection --- random forest --- Decision tree --- personalized precision oncology --- circulating free DNA --- liquid biopsy --- epidermal growth factor receptor --- tyrosine kinase inhibitor --- osimertinib --- comprehensive genomic profiling --- molecular genotyping --- intratumor heterogeneity --- multiple biopsies --- tumor evolution --- clonality classification --- strategic therapeutic intervention --- thymoma --- driver mutation --- sequencing --- molecular barcoding --- EGFR mutation --- EGFR-TKI --- cfDNA --- NGS --- digital enrichment --- next-generation sequencing --- solid cancer --- universal health-care system --- precision medicine --- presumed germline findings --- clinical guideline --- non-small cell lung cancer --- outcome --- adjuvant chemotherapy --- anaplastic lymphoma receptor tyrosine kinase --- HNSCC --- ctDNA --- tDNA --- DDR genes --- PARP inhibitors --- new drug development --- next-generation sequencing (NGS) --- open data --- regulatory reform --- tumor profiling test --- triple-negative breast cancer (TNBC) --- breast cancer --- targeted therapy --- TNBC subtypes --- immunotherapy --- cancer --- screening --- smoking --- electronic records --- PD-L1 --- cancer-associated fibroblasts --- resistance --- chemotherapy --- CTC --- immunocytochemistry --- parallel double-detection --- laboratory-friendly --- n/a
Choose an application
In the era of precision medicine, the use of molecularly targeted therapies in selected patients has led to a paradigm change in cancer treatment. Multiple studies have demonstrated the benefits of therapies that are chosen based on the molecular profile of the tumor and also from the liquid biopsy. With genomics' increasing ability, a routine transcriptomics analysis of advanced/metastatic cancers is now feasible in most cancer hospitals, including community cancer centers. This is an unprecedented shift in the management of cancers irrespective of their organ types, which not only improved the outcome but also opened several new avenues in research and practice, such as immune-check-point inhibitors, tumor-TME co-evolution in the development of resistance, longitudinal liquid biopsies, biomarkers screening and the management of electronic medical records.This book brings together these crucial areas of investigation. The research presented here attempts to address the current issues to provoke thoughts for the future. The future of precision medicine will have to embrace a shift from in vitro, in vivo/PDX models for the mechanistic study to a more functional test based on the scientific interrogation of genomic data, in the form of functional precision medicine. We will also have to combat the element of noise in the multitudes of data and impart the regulatory structure to make judicious use of the data. The expectations for functional precision medicine are high. We aspire to witness a tremendous improvement in patient outcomes, from better to best, down the road that will match the clinical guidelines.
Medicine --- Oncology --- pediatric tumors --- tumor mutational burden --- TMB --- whole-exome sequencing --- gene panel sequencing --- immune checkpoint inhibitors --- glioblastoma prognosis --- overall survival --- extent of resection --- random forest --- Decision tree --- personalized precision oncology --- circulating free DNA --- liquid biopsy --- epidermal growth factor receptor --- tyrosine kinase inhibitor --- osimertinib --- comprehensive genomic profiling --- molecular genotyping --- intratumor heterogeneity --- multiple biopsies --- tumor evolution --- clonality classification --- strategic therapeutic intervention --- thymoma --- driver mutation --- sequencing --- molecular barcoding --- EGFR mutation --- EGFR-TKI --- cfDNA --- NGS --- digital enrichment --- next-generation sequencing --- solid cancer --- universal health-care system --- precision medicine --- presumed germline findings --- clinical guideline --- non-small cell lung cancer --- outcome --- adjuvant chemotherapy --- anaplastic lymphoma receptor tyrosine kinase --- HNSCC --- ctDNA --- tDNA --- DDR genes --- PARP inhibitors --- new drug development --- next-generation sequencing (NGS) --- open data --- regulatory reform --- tumor profiling test --- triple-negative breast cancer (TNBC) --- breast cancer --- targeted therapy --- TNBC subtypes --- immunotherapy --- cancer --- screening --- smoking --- electronic records --- PD-L1 --- cancer-associated fibroblasts --- resistance --- chemotherapy --- CTC --- immunocytochemistry --- parallel double-detection --- laboratory-friendly --- pediatric tumors --- tumor mutational burden --- TMB --- whole-exome sequencing --- gene panel sequencing --- immune checkpoint inhibitors --- glioblastoma prognosis --- overall survival --- extent of resection --- random forest --- Decision tree --- personalized precision oncology --- circulating free DNA --- liquid biopsy --- epidermal growth factor receptor --- tyrosine kinase inhibitor --- osimertinib --- comprehensive genomic profiling --- molecular genotyping --- intratumor heterogeneity --- multiple biopsies --- tumor evolution --- clonality classification --- strategic therapeutic intervention --- thymoma --- driver mutation --- sequencing --- molecular barcoding --- EGFR mutation --- EGFR-TKI --- cfDNA --- NGS --- digital enrichment --- next-generation sequencing --- solid cancer --- universal health-care system --- precision medicine --- presumed germline findings --- clinical guideline --- non-small cell lung cancer --- outcome --- adjuvant chemotherapy --- anaplastic lymphoma receptor tyrosine kinase --- HNSCC --- ctDNA --- tDNA --- DDR genes --- PARP inhibitors --- new drug development --- next-generation sequencing (NGS) --- open data --- regulatory reform --- tumor profiling test --- triple-negative breast cancer (TNBC) --- breast cancer --- targeted therapy --- TNBC subtypes --- immunotherapy --- cancer --- screening --- smoking --- electronic records --- PD-L1 --- cancer-associated fibroblasts --- resistance --- chemotherapy --- CTC --- immunocytochemistry --- parallel double-detection --- laboratory-friendly
Choose an application
Background: The gut microbiota is emerging as a pivotal player in the pathogenesis of many non-communicable diseases. Thus, it has been proposed as a new diagnostic and therapeutic target.Aim and scope: This Special Issue will focus on the microbiome as a potential target of new personalized therapies or diagnostic tools.History: In recent decades, the gut microbiome has been deeply investigated, and many studies have provided new information on the role of dysbiosis in many gastrointestinal and extra-gastrointestinal diseases. Recently, in addition to its phylogenetic characterization, new information has become available regarding the function of the gut microbiota, thanks to proteomic and metabolomic analyses.Cutting-edge research: The therapeutic modulation of the gut microbiota based on different strategies, including diet modification, antibiotics, prebiotics, probiotics, and, last but not least, fecal microbiota transplantation, has been tested for the treatment of various diseases. Recently, the possible applications and modalities of gut microbiota modulation have been increasingly expanding.We have collected original clinical or pre-clinical research papers and reviews focusing on the use of the microbiome for disease diagnosis, monitoring, or therapy and suggesting new possible gut microbiota-based approaches for personalized care.
Medicine --- Graves–Basedow’s diseases --- Hashimoto’s thyroiditis --- autoimmunity --- gut microbiota --- irritable bowel syndrome --- microbiota --- microbiome --- food components --- nutrients --- hematopoietic stem cell transplantation --- fecal microbiota transplantation --- aGvHD --- antibiotic-resistant bacteria --- cystic fibrosis --- rabbits --- intestinal dysbiosis --- feces microbiome --- beta-blocker --- hemodialysis --- next-generation sequencing --- propensity score matching methods --- violin plots --- random sampling --- analytical reproducibility --- fecal matter transplantation --- data disease subtypes --- personalized medicine --- maltodextrin --- dip test --- gallstone disease --- 16S rDNA gene diversity --- blood biochemical characteristics --- mesothelioma --- 16S RNA sequencing --- species --- probiotics and gut disease --- probiotics and acute diverticulitis --- probiotics and diverticular disease --- probiotics mechanism of action --- IgA Nephropathy --- rifaximin --- α1KI-CD89Tg mice --- children --- intermittent hypoxemia --- obstructive sleep apnea --- tonsil --- weight status --- oral microbiota --- rheumatology diseases --- biomarkers --- artificial intelligence --- machine learning --- rheumatoid arthritis --- Sjogren’s syndrome --- systemic lupus erythematosus --- endometrial cancer --- endometrial microbiome --- gut microbiome --- dysbiosis --- estrogen metabolism --- estrobolome --- inflammation --- antitumour treatment --- prebiotics --- probiotics --- schizophrenia --- depression --- anxiety --- functional genes --- thymoma --- genera --- driver mutation --- cardiovascular diseases --- critically ill --- intestinal permeability --- recurrent cystitis --- n/a --- Graves-Basedow's diseases --- Hashimoto's thyroiditis --- Sjogren's syndrome
Choose an application
Physical methods for diagnosis --- Radiotherapy. Isotope therapy --- Medical radiology --- Nuclear medicine --- Radiography --- Radiology --- Radiologie médicale --- Médecine nucléaire --- Radiographie --- Radiologie --- Periodicals --- Périodiques --- Neoplasms --- Nuclear Medicine. --- Radiography. --- Radiology. --- Medical radiology. --- radiotherapy. --- Medicine, Atomic --- Medicine, Nuclear --- Radiology, Nuclear --- Atomic Medicine --- Nuclear Radiology --- Nuclear Pharmacy --- Radiobiology --- Diagnostic X-Ray --- Diagnostic X-Ray Radiology --- X-Ray Radiology, Diagnostic --- Radiology, Diagnostic X-Ray --- Roentgenography --- X-Ray, Diagnostic --- Diagnostic X Ray --- Diagnostic X Ray Radiology --- Diagnostic X-Rays --- Radiology, Diagnostic X Ray --- X Ray Radiology, Diagnostic --- X Ray, Diagnostic --- X-Rays, Diagnostic --- Radiologic and Imaging Nursing --- Health Sciences --- General and Others --- Pharmacy and Pharmacology --- Health Sciences. --- General and Others. --- Radiologie médicale --- Médecine nucléaire --- Périodiques --- ARRS-E EJMEDEC EPUB-ALPHA-A EPUB-PER-FT MDRADIOL --- Clinical radiology --- Radiology, Medical --- Radiology (Medicine) --- radiotherapy --- Nuclear Medicine --- MDRADIOL --- Medical physics --- Benign Neoplasms --- Malignancy --- Malignant Neoplasms --- Neoplasia --- Neoplasm --- Neoplasms, Benign --- Cancer --- Tumors --- Benign Neoplasm --- Cancers --- Malignancies --- Malignant Neoplasm --- Neoplasias --- Neoplasm, Benign --- Neoplasm, Malignant --- Neoplasms, Malignant --- Tumor --- Medical Oncology --- Radiotherapie. Isotopentherapie --- Fysische diagnosetechnieken --- Journal --- Radiologia mèdica --- Medicina nuclear --- neoplasms. --- radiography. --- radiology. --- Radiologia mèdica. --- Medicina nuclear. --- Isòtops radioactius en medicina --- Medicina atòmica --- Cobaltoteràpia --- Isòtops radioactius en diagnòstic mèdic --- Isòtops radioactius en farmacologia --- Radiologia clínica --- Radiologia (Medicina) --- Física mèdica --- Radiofàrmacs --- Radiografia mèdica --- Radiologia dental --- Radiologia intervencionista --- Radiologia pediàtrica --- Radiologia veterinària --- Radioteràpia --- Diagnòstic radiològic --- medical sciences --- radiation safety --- radiography --- radionuclides --- X-radiation --- cinefluorography --- cineradiography --- roentgenography --- methodology --- angiography --- autoradiography --- dual-energy X-ray absorptiometry --- neuroradiography --- diagnostic techniques --- radiology --- radiation therapy --- therapeutics --- brachytherapy --- irradiation --- radiation injury --- radio-sensitizing agents --- cancer (disease) --- cancers --- neoplasia --- tumors --- tumours --- noninfectious diseases --- adenoma --- brain neoplasms --- breast neoplasms --- carcinoma --- colorectal neoplasms --- digestive system neoplasms --- fibroma --- glioma --- head and neck neoplasms --- hemangioma --- kidney neoplasms --- laryngeal neoplasms --- leukemia --- lipoma --- liver neoplasms --- lung neoplasms --- lymphoma --- mammary neoplasms (animal) --- melanoma --- mesothelioma --- odontogenic neoplasms --- ovarian neoplasms --- pancreatic neoplasms --- papilloma --- prostatic neoplasms --- sarcoid --- sarcoma --- skin neoplasms --- splenic neoplasms --- thymoma --- transmissible venereal tumors --- urinary bladder neoplasms --- uterine neoplasms --- warts --- anticarcinogenic agents --- antineoplastic activity --- antineoplastic agents --- cancer vaccines --- carcinogenesis --- diet-related diseases --- metastasis --- neoplasm antigens --- neoplasm cells --- Nuclear medicine. --- Médecine nucléaire. --- Radiographie. --- Radiologie. --- Radiological physics --- Physics --- Radiation --- Skiagraphy --- X-ray photography --- Photography --- X-rays --- Atomic medicine --- Radioisotopes in medicine --- Radioactive tracers --- Radioactivity --- Scientific applications --- Physiological effect --- MDRADIOL MDNUCLEA --- Radiology, Medical - Periodicals --- Neoplasms - radiotherapy - periodicals --- Nuclear Medicine - Periodicals --- Radiography - periodicals --- Radiology - Periodicals
Listing 1 - 6 of 6 |
Sort by
|